LifeCycle Pharma Announces Transplantation Programs on Track

HORSHOLM, Denmark--(BUSINESS WIRE)--LifeCycle Pharma A/S (OMX: LCP), an emerging specialty pharmaceutical company, announced today positive interim results from an ongoing Phase II clinical trial for LCP-Tacro in stable liver transplant patients.
MORE ON THIS TOPIC